Emmes, a Clinical Research Organization (CRO) with a passion for advancing public health and biopharmaceutical innovation, has taken a leap forward with the acquisition of Essex Management. Essex is a renowned provider of bioinformatics and health information technology (HIT) consulting services to government, private sector, and academic organizations.
This acquisition is a game-changer for Emmes, allowing it to provide clients with the most advanced solutions and expand its services. With the addition of Essex, Emmes will now be able to blaze new trails in clinical research and provide cutting-edge data strategies for biopharma clients.
The merger of Emmes and Essex will result in a clinical research powerhouse that’s pushing the boundaries of innovation. With the combined power of Emmes’ advanced analytics solutions and Essex’s technology skills, the CRO will be better equipped to tackle global health challenges and spark a clinical research evolution.
Essex’s reputation as a technology catalyst in the life sciences, combined with Emmes’ successful partnerships with the National Cancer Institute (NCI) and other public sector clients, will ignite a spark that will drive growth and bring a new level of innovation to the field of clinical research.
